These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19604090)

  • 1. Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer.
    Kong SY; Lim HS; Nam BH; Kook MC; Kim YW; Ryu KW; Lee JH; Choi IJ; Lee JS; Park YI; Kim NK; Park SR
    Pharmacogenomics; 2009 Jul; 10(7):1147-55. PubMed ID: 19604090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.
    Jeong JH; Park SR; Ahn Y; Ryu MH; Ryoo BY; Kong SY; Yook JH; Yoo MW; Kim BS; Kim BS; Kang YK
    Gastric Cancer; 2017 Jan; 20(1):146-155. PubMed ID: 26715117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients.
    Park SR; Kong SY; Nam BH; Choi IJ; Kim CG; Lee JY; Cho SJ; Kim YW; Ryu KW; Lee JH; Rhee J; Park YI; Kim NK
    Br J Cancer; 2011 Mar; 104(7):1126-34. PubMed ID: 21364592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival.
    Kim YW; Kim MJ; Ryu KW; Lim HS; Lee JH; Kong SY; Lee JS; Choi IJ; Kim CG; Lee JY; Cho SJ; Kook MC; Park YI; Kim SK; Park SR
    Gastric Cancer; 2016 Apr; 19(2):586-596. PubMed ID: 25851942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity.
    Choi YH; Kim TW; Kim KP; Lee SS; Hong YS; Ryu MH; Lee JL; Chang HM; Ryoo BY; Kim HS; Shin JG; Kang YK
    Oncology; 2012; 82(5):290-7. PubMed ID: 22555197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.
    Kim KP; Jang G; Hong YS; Lim HS; Bae KS; Kim HS; Lee SS; Shin JG; Lee JL; Ryu MH; Chang HM; Kang YK; Kim TW
    Br J Cancer; 2011 Feb; 104(4):605-12. PubMed ID: 21326246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The influence of CYP2A6 polymorphism on adjuvant S-1 chemotherapy outcomes in patients with curatively resected gastric cancer].
    Hu FK; Shen J; Gao SW
    Zhonghua Yi Xue Za Zhi; 2018 Jun; 98(24):1915-1918. PubMed ID: 29996281
    [No Abstract]   [Full Text] [Related]  

  • 8. Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy.
    Fang WJ; Mou HB; Jin DZ; Zheng YL; Zhao P; Mao CY; Peng L; Huang MZ; Xu N
    Oncol Rep; 2012 May; 27(5):1606-10. PubMed ID: 22322240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results.
    Kim MJ; Kong SY; Nam BH; Kim S; Park YI; Park SR
    Pharmacogenet Genomics; 2018 Jan; 28(1):23-30. PubMed ID: 29189588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
    Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
    Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
    Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.
    Daigo S; Takahashi Y; Fujieda M; Ariyoshi N; Yamazaki H; Koizumi W; Tanabe S; Saigenji K; Nagayama S; Ikeda K; Nishioka Y; Kamataki T
    Pharmacogenetics; 2002 Jun; 12(4):299-306. PubMed ID: 12042667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
    Fujita K; Yamamoto W; Endo S; Endo H; Nagashima F; Ichikawa W; Tanaka R; Miya T; Araki K; Kodama K; Sunakawa Y; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Kamataki T; Sasaki Y
    Cancer Sci; 2008 May; 99(5):1049-54. PubMed ID: 18380793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?
    Ishii Y; Suzuki S; Takahashi Y; Takayama T; Asai S
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):333-43. PubMed ID: 19921195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
    Ajani JA; Rodriguez W; Bodoky G; Moiseyenko V; Lichinitser M; Gorbunova V; Vynnychenko I; Garin A; Lang I; Falcon S
    J Clin Oncol; 2010 Mar; 28(9):1547-53. PubMed ID: 20159816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.
    Jeung HC; Rha SY; Im CK; Shin SJ; Ahn JB; Yang WI; Roh JK; Noh SH; Chung HC
    Cancer; 2011 May; 117(10):2050-7. PubMed ID: 21523716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.
    Hirose T; Fujita K; Nishimura K; Ishida H; Yamashita K; Sunakawa Y; Mizuno K; Miwa K; Nagashima F; Tanigawara Y; Adachi M; Sasaki Y
    Oncol Rep; 2010 Aug; 24(2):529-36. PubMed ID: 20596643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
    Hironaka S; Yamazaki K; Taku K; Yokota T; Shitara K; Kojima T; Ueda S; Machida N; Muro K; Boku N
    Jpn J Clin Oncol; 2010 Nov; 40(11):1014-20. PubMed ID: 20603245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
    Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
    Yoshida K; Ninomiya M; Takakura N; Hirabayashi N; Takiyama W; Sato Y; Todo S; Terashima M; Gotoh M; Sakamoto J; Nishiyama M
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3402-7. PubMed ID: 16740764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.